SCHEDULE 13D/A: Activist Investor Demands Aadi Bioscience Records Over Rejected Acquisition Bids and Dilutive Financing

Aadi Bioscience, Inc. faces a demand for books and records from activist investor BML Investment Partners, L.P. and Braden M. Leonard, who allege mismanagement, rejected favorable acquisition offers, and a highly dilutive financing deal that benefited insiders.

Summary

• BML Investment Partners, L.P. and Braden M. Leonard, collectively holding 9.9% of Aadi Bioscience, Inc.'s common stock, have filed an amended Schedule 13D and issued a demand letter to the company's Board of Directors.
• The demand seeks to inspect books and records related to the Board's decision to reject multiple favorable acquisition proposals for the entire company in 2024.
• Specifically, Bidder A offered $3.11 per share (70% premium over September 19, 2024 closing price of $1.83) plus a contingent value right of up to $20.0 million on September 20, 2024.
• Kaken Pharmaceutical Co., Ltd. offered $80.0 million for the entire company on October 17, 2024 (145% premium over October 15, 2024 closing price of $2.13), which the Board estimated would result in $4.38 to $4.74 per share.
• Instead of an acquisition, the Board pursued a divestiture of Aadi's main asset, FYARRO, to Kaken for $100 million, announced on December 19, 2024, which the investors claim leaves Aadi with risky preclinical assets.
• Concurrently, Aadi announced a $100 million PIPE (Private Investment in Public Equity) financing on December 19, 2024, involving the issuance of 21,592,000 common shares at $2.40 per share and 20,076,500 pre-funded warrants.
• The PIPE financing is highly dilutive, potentially accounting for approximately 61% of total shares outstanding post-exercise, representing approximately 150% dilution of pre-PIPE shares.
• The investors allege the PIPE was undertaken on unfavorable terms, despite warnings from the company's investment banking firm, Jefferies, LLC, about low investor interest and resistance to premium pricing.
• Insiders, including at least four Board members, are participating in the PIPE financing, acquiring shares at a substantial discount to dissolution value, raising concerns about self-interest and conflicts of interest.
• The demand letter states that the disclosure of the Divestiture Agreement was delayed to coincide with the PIPE Financing, enabling PIPE investors to justify a lower price and more favorable terms.
• The purpose of the demand is to investigate potential mismanagement, negligence, destruction of shareholder value, breaches of fiduciary duty, and other legal violations by the Board, and to determine whether to institute litigation or other corrective actions.

Sentiment

Score: 2

Explanation: The document expresses strong negative sentiment from the activist investor, alleging mismanagement, destruction of shareholder value, and self-interested actions by the Board, particularly concerning rejected acquisition offers and a highly dilutive financing deal.

Negatives

• The Board rejected multiple favorable acquisition proposals for the entire company, including a $3.11 per share offer (70% premium) and an $80.0 million offer (145% premium), in favor of a partial asset sale and dilutive financing.
• The divestiture of FYARRO, Aadi's sole product sales source ($7.2 million in Q3 2024, $18.7 million for nine months ended Sept 30, 2024), for $100 million leaves the company with a portfolio of highly risky preclinical assets.
• The $100 million PIPE financing is highly dilutive, potentially resulting in approximately 150% dilution of pre-PIPE shares, with new securities accounting for about 61% of total shares outstanding.
• The PIPE financing was priced at a discount, despite Jefferies' warnings about low investor interest and resistance to premium pricing, suggesting unfavorable terms for existing shareholders.
• At least four Board members and other insiders, controlling over 30% of currently outstanding shares, are participating in the PIPE, raising concerns about self-interested transactions and conflicts of interest.
• The delay in disclosing the FYARRO divestiture until it was announced simultaneously with the PIPE financing is alleged to have enabled PIPE investors to secure lower prices and more favorable terms.

Risks

• Risk of significant shareholder dilution due to the PIPE financing, potentially reducing the value of existing shares.
• Risk associated with the company's future relying on a portfolio of highly risky preclinical assets after divesting its main revenue-generating product, FYARRO.
• Potential for litigation or other corrective actions by activist shareholders due to alleged mismanagement, breaches of fiduciary duty, and destruction of shareholder value.
• Concerns regarding corporate governance and Board independence, particularly concerning the Board's decision-making process for the divestiture and PIPE financing, and insider participation.
• Uncertainty regarding the company's ability to generate future revenue and achieve value inflection points from its new preclinical pipeline.

Future Outlook

The reporting persons reserve the right to acquire or dispose of additional securities of Aadi Bioscience, Inc. and to formulate other plans or proposals regarding the Issuer. The demand for books and records is a precursor to potential litigation or other corrective actions to address alleged mismanagement and breaches of fiduciary duty by the Board.

Management Comments

• The Board appears to have rejected both acquisition proposals in favor of pursuing a sale of only FYARRO and then purchasing a portfolio of risky pre-clinical assets from a Chinese company, at least in part for self-interested reasons.
• The Board did not obtain a fairness opinion to ensure the terms of the PIPE Financing were in the best interest of the Company stockholders.
• The Board pressed ahead with the PIPE Financing despite Jefferies' warnings that a PIPE was inadvisable due to little interest from potential investors and resistance to pricing at a substantial premium.
• The Board delayed disclosure of the Divestiture Agreement and instead announced it simultaneously with the PIPE Financing, enabling the PIPE Investors to justify a lower price and more favorable terms.
• The Board's pursuit of the PIPE Financing was, at best, reckless, and potentially appears to have been motivated by self-interest.
• The Board failed to maximize stockholder value (including with respect to the October Kaken Bid), despite the potentially tremendous opportunities available to stockholders.
• The Board owed fiduciary duties to protect the interests of stockholders and guard against self-interest and potential conflicts with management.

Industry Context

This filing highlights a common scenario in the biotechnology and pharmaceutical industry where companies with approved products (like FYARRO) are targets for acquisition. The decision to divest a key asset and pursue dilutive financing, especially when more favorable full-company acquisition offers were on the table, can be a point of contention for investors. The involvement of board members in the PIPE financing also raises corporate governance concerns, a recurring theme in public companies, particularly in sectors requiring significant capital for R&D.

Comparison to Industry Standards

• The rejected acquisition offers (70% and 145% premiums) represent significant value propositions that, in many industry contexts, would be seriously considered or accepted to maximize immediate shareholder value, especially for a company with a single approved product.
• The PIPE financing terms, described as 'dilutive' and 'discounted' with 'little interest from potential investors' and resistance to premium pricing, appear to fall below typical industry standards for capital raises that aim to be non-dilutive or minimally dilutive, especially when a company has just divested a revenue-generating asset.
• The participation of Board members in a dilutive PIPE financing, particularly when a fairness opinion was not obtained, deviates from best practices in corporate governance aimed at avoiding conflicts of interest and ensuring transactions are at arm's length and in the best interest of all shareholders.
• The decision to sell the 'main asset' (FYARRO) and pivot to 'risky pre-clinical assets' while rejecting higher bids for the entire company contrasts with strategies often seen in the biotech sector where companies with approved drugs are acquired for their commercialized assets and pipeline, rather than divesting the core asset and retaining early-stage, high-risk programs.

Corporate Governance

Legal Proceedings

• The demand for inspection of books and records pursuant to 8 Del. C. 220 is a formal step that often precedes litigation, indicating potential future legal proceedings against the company's Board of Directors.

Related Party Transactions

• Entities affiliated with at least four members of the Board are participating in the PIPE Financing, acquiring shares at a substantial discount to dissolution value, which the reporting persons allege is a self-interested transaction.

Stakeholder Impact

• **Shareholders**: Directly impacted by the alleged destruction of shareholder value due to rejected acquisition offers and significant dilution from the PIPE financing. Existing shareholders' equity stake and per-share value are negatively affected.
• **Management/Board**: Their employment and compensation are preserved through the current strategy, but they face scrutiny and potential legal action from activist investors regarding their decisions and alleged conflicts of interest.
• **Creditors**: While not explicitly detailed, a company's strategic decisions and financial health can indirectly affect its creditworthiness and ability to meet obligations.
• **Employees**: The shift from a commercialized product to a preclinical pipeline could imply changes in operational focus and potentially future staffing needs, though not directly stated.

Next Steps

• Aadi Bioscience, Inc. is requested to respond to the demand for inspection of books and records no later than five business days after its receipt.
• The reporting persons will evaluate the inspected documents to determine whether to institute litigation, make a formal demand on the Board, or take other corrective actions.
• The reporting persons may communicate with other Aadi stockholders concerning the company's governance.
• The reporting persons reserve the right to acquire or dispose of additional securities of the Issuer.

Key Dates

Keywords

Aadi Bioscience, BML Investment Partners, Braden M. Leonard, Schedule 13D, Activist Investor, Shareholder Activism, Corporate Governance, SEC Filing, Books and Records Demand, Delaware General Corporation Law Section 220, FYARRO, PEComa, Asset Divestiture, PIPE Financing, Private Investment in Public Equity, Share Dilution, Acquisition Proposals, Kaken Pharmaceutical, Jefferies LLC, Fiduciary Duty, Mismanagement, Shareholder Value